AYTU Aytu Biopharma Inc

Price (delayed)

$3.08

Market cap

$17.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.85

Enterprise value

$13.66M

Highlights
AYTU's EPS has soared by 91% YoY and by 35% QoQ
The company's net income has surged by 77% YoY and by 26% QoQ
Aytu Biopharma's equity has decreased by 28% YoY but it has increased by 2.1% QoQ
AYTU's revenue is down by 7% YoY and by 3.3% QoQ

Key stats

What are the main financial stats of AYTU
Market
Shares outstanding
5.57M
Market cap
$17.15M
Enterprise value
$13.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
0.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.14
Earnings
Revenue
$98.5M
EBIT
-$17.17M
EBITDA
-$8.45M
Free cash flow
$6.11M
Per share
EPS
-$3.85
Free cash flow per share
$1.11
Book value per share
$5.9
Revenue per share
$17.85
TBVPS
$13.69
Balance sheet
Total assets
$131.25M
Total liabilities
$98.4M
Debt
$16.04M
Equity
$32.85M
Working capital
$7.18M
Liquidity
Debt to equity
0.49
Current ratio
1.11
Quick ratio
0.76
Net debt/EBITDA
0.41
Margins
EBITDA margin
-8.6%
Gross margin
63.2%
Net margin
-18.3%
Operating margin
-8.9%
Efficiency
Return on assets
-13.1%
Return on equity
-49.5%
Return on invested capital
-339.8%
Return on capital employed
-25.6%
Return on sales
-17.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AYTU stock price

How has the Aytu Biopharma stock price performed over time
Intraday
0%
1 week
6.57%
1 month
8.45%
1 year
46.67%
YTD
8.45%
QTD
8.45%

Financial performance

How have Aytu Biopharma's revenue and profit performed over time
Revenue
$98.5M
Gross profit
$62.29M
Operating income
-$8.73M
Net income
-$18M
Gross margin
63.2%
Net margin
-18.3%
Aytu Biopharma's operating income has soared by 89% YoY and by 51% from the previous quarter
Aytu Biopharma's operating margin has surged by 88% YoY and by 49% QoQ
The company's net income has surged by 77% YoY and by 26% QoQ
The company's net margin has surged by 75% YoY and by 24% QoQ

Growth

What is Aytu Biopharma's growth rate over time

Valuation

What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.52
P/S
0.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.14
AYTU's EPS has soared by 91% YoY and by 35% QoQ
The P/B is 73% above the last 4 quarters average of 0.3 but 60% below the 5-year quarterly average of 1.3
Aytu Biopharma's equity has decreased by 28% YoY but it has increased by 2.1% QoQ
AYTU's P/S is 87% below its 5-year quarterly average of 1.3 but 70% above its last 4 quarters average of 0.1
AYTU's revenue is down by 7% YoY and by 3.3% QoQ

Efficiency

How efficient is Aytu Biopharma business performance
AYTU's ROS has soared by 76% YoY and by 28% QoQ
The ROA has soared by 75% YoY and by 25% from the previous quarter
Aytu Biopharma's ROIC has soared by 75% YoY and by 16% from the previous quarter
The ROE has soared by 68% YoY and by 20% from the previous quarter

Dividends

What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AYTU.

Financial health

How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 33% higher than its total liabilities
Aytu Biopharma's quick ratio has increased by 13% YoY
Aytu Biopharma's total assets has decreased by 7% YoY
The company's debt is 51% lower than its equity
Aytu Biopharma's equity has decreased by 28% YoY but it has increased by 2.1% QoQ
The company's debt fell by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.